CABA-201 for Lupus
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new cell therapy called CABA-201 for patients with active lupus. It aims to help those whose disease is not well-controlled by current treatments. Patients first get standard medications to prepare their bodies, then receive CABA-201 to help manage their immune system.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Who Is on the Research Team?
Medical Director
Principal Investigator
Cabaletta Bio
Are You a Good Fit for This Trial?
Adults aged 18-65 with active Systemic Lupus Erythematosus (SLE) can join. For lupus nephritis, a biopsy must confirm it. Participants need positive tests for specific antibodies and have moderate to severe SLE symptoms if not renal-related. Exclusions include other kidney diseases, previous CAR T cell therapy, reactions to certain drugs, ongoing serious infections or organ transplants.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Preconditioning
Participants receive a standard regimen including cyclophosphamide (CY) and fludarabine (FLU) before the infusion of CABA-201
Treatment
Participants receive a single dose of CABA-201
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CABA-201
CABA-201 is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cabaletta Bio
Lead Sponsor